|
|
 |
|
|
|
|
103. C. Kohler and V. Chan-Palay. Cholecystokinin-octapeptide (CCK-8) receptors in the hippocampal region: a comparative in vitro autoradiographic study in the rat, monkey and the post mortem brain. Neurosci. Lett. 90: 5156, 1988. |
|
|
|
|
|
|
|
|
104. D. Comar (1995). PET for Drug Development and Evaluation. D. Comar, Ed. Developments in Nuclear Medicine, Vol. 26. Kluwer Academic Publishers Group, The Netherlands. |
|
|
|
|
|
|
|
|
105. L. P. Balant, M. Rowland, L. Aarons, F. Mentré, P. L. Morselli, J. L. Steimer, and A. Vozeh. New strategies in drug development and clinical evaluation: the population approach. Eur. J. Clin. Pharmacol. 45: 9394, 1993. |
|
|
|
|
|
|
|
|
106. J. Grevel, B. Whiting, A. W. Kelman, and K. Kutz. Compilation of a clinical pharmacokinetic database for population analysis during drug development. Pharma. Med. 2: 127136, 1987. |
|
|
|
|
|
|
|
|
107. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, J. H. Rodman, L. Sanathanan, J. J. Schentag, V. P. Shah, L. B. Sheiner, J. P. Skelly, D. R. Stanski, R. J. Temple, C. T. Viswanathan, J. Weissinger, and A. Yacobi. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm. Res. 9: 826833, 1992. |
|
|
|
|
|
|
|
|
108. J. Van Bree, J. Nedelman, J.-L. Steimer, F. Tse, W. Robinson, and W. Niederberger. Application of sparse sampling approaches in rodent toxicokinetics: A prospective view. Drug Inf. J. 28: 263279, 1994. |
|
|
|
|
|
|
|
|
109. S. L. Beal and L. B. Sheiner. The NONMEM system. Amer. Stat. 34: 118, 1982. |
|
|
|
|
|
|
|
|
110. R. P. Gomeni. Pharm: A population pharmacokinetic pharmacodynamic data modelling software. SIMED, Creteil, France, 1994. |
|
|
|
|
|
|
|
|
111. R. Jochemsen, D. Bazot, M. H. Brillance, and M. Lupart. Assessment of drug exposure in rat dietary studies. Xenobiotica 23: 11451154, 1993. |
|
|
|
|
|
|
|
|
112. L. Chasseaud. Personal communication, 1995. |
|
|
|
|
|